BRPI0907624A2 - tratamento e prevenção de doenças cardíacas usando duas ou mais isoformas do fator de crescimento de hepatócito - Google Patents

tratamento e prevenção de doenças cardíacas usando duas ou mais isoformas do fator de crescimento de hepatócito

Info

Publication number
BRPI0907624A2
BRPI0907624A2 BRPI0907624A BRPI0907624A BRPI0907624A2 BR PI0907624 A2 BRPI0907624 A2 BR PI0907624A2 BR PI0907624 A BRPI0907624 A BR PI0907624A BR PI0907624 A BRPI0907624 A BR PI0907624A BR PI0907624 A2 BRPI0907624 A2 BR PI0907624A2
Authority
BR
Brazil
Prior art keywords
prevention
growth factor
heart disease
hepatocyte growth
disease treatment
Prior art date
Application number
BRPI0907624A
Other languages
English (en)
Inventor
Jong-Mook Kim
Sujeong Kim
Woong Hahn
Original Assignee
Viromed Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viromed Co Ltd filed Critical Viromed Co Ltd
Publication of BRPI0907624A2 publication Critical patent/BRPI0907624A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BRPI0907624A 2008-01-25 2009-01-28 tratamento e prevenção de doenças cardíacas usando duas ou mais isoformas do fator de crescimento de hepatócito BRPI0907624A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2375608P 2008-01-25 2008-01-25
PCT/KR2009/000406 WO2009093880A2 (en) 2008-01-25 2009-01-28 Treatment and prevention of cardiac conditions using two or more isoforms of hepatocyte growth factor

Publications (1)

Publication Number Publication Date
BRPI0907624A2 true BRPI0907624A2 (pt) 2016-08-16

Family

ID=40901564

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0907624A BRPI0907624A2 (pt) 2008-01-25 2009-01-28 tratamento e prevenção de doenças cardíacas usando duas ou mais isoformas do fator de crescimento de hepatócito

Country Status (14)

Country Link
US (1) US20090202606A1 (pt)
EP (1) EP2252321B1 (pt)
JP (1) JP5563991B2 (pt)
KR (1) KR101325674B1 (pt)
CN (1) CN101925362A (pt)
AU (1) AU2009206869B2 (pt)
BR (1) BRPI0907624A2 (pt)
CA (1) CA2712078C (pt)
DK (1) DK2252321T3 (pt)
ES (1) ES2537971T3 (pt)
MX (1) MX2010007887A (pt)
PT (1) PT2252321E (pt)
RU (1) RU2448159C1 (pt)
WO (1) WO2009093880A2 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8409214B2 (en) * 2009-01-22 2013-04-02 Meditech Development Incorporated Portable regulated vacuum pump for medical procedures
KR100562824B1 (ko) 2002-03-20 2006-03-23 주식회사 바이로메드 유전자 발현효율이 높으며 간세포 성장인자의 두 가지이형체를 동시에 발현하는 하이브리드 간세포 성장인자유전자
JP5579164B2 (ja) * 2008-04-09 2014-08-27 ビロメッド カンパニー， リミテッド 凍結乾燥ｄｎａ製剤、組成物、及び凍結乾燥ｄｎａ製剤を製造する方法
CA2853918C (en) * 2011-11-03 2020-12-29 Viromed Co., Ltd. Gene therapy for diabetic neuropathy using an hgf isoform
US10639351B2 (en) 2013-10-22 2020-05-05 Helixmith Co., Ltd. Method for treating amyotrophic lateral sclerosis with a polynucleotide encoding two or more isoforms of hepatocyte growth factor
CN103519900A (zh) * 2013-10-24 2014-01-22 河南科技大学第一附属医院 一种心胸外科护肺膜
KR101567954B1 (ko) * 2013-11-25 2015-11-11 인하대학교 산학협력단 Hgf 단백질 또는 그 유전자를 포함하는 발기부전 예방 또는 치료용 조성물 및 그의 용도
CN106536056B (zh) 2014-06-13 2021-07-16 儿童医学中心公司 分离线粒体的产品和方法
JP6532141B2 (ja) * 2014-09-26 2019-06-19 ヘリックスミス カンパニー リミテッド 肝細胞増殖因子及びストローマ細胞由来因子１αを用いた末梢動脈疾患の予防または治療用組成物
ES2761852T3 (es) 2015-01-21 2020-05-21 Centre Nat Rech Scient Proteínas agonistas del receptor MET
WO2017124037A1 (en) 2016-01-15 2017-07-20 The Children's Medical Center Corporation Therapeutic use of mitochondria and combined mitochondrial agents
WO2018167447A1 (en) * 2017-03-14 2018-09-20 University Of Sheffield Low dose aspirin (1-50 mg) together with antiplatelets such as ticagrelor of anticoagulants
CN109771642B (zh) 2017-11-13 2022-09-20 同济大学苏州研究院 c-MET激动型抗体及其用途
EP3823981A4 (en) 2018-07-17 2022-04-06 Neuromyon Inc. TREATMENT OF NEUROPATHY WITH DNA CONSTRUCTS EXPRESSING IGF-1 ISOFORMS
KR20210027493A (ko) 2018-07-19 2021-03-10 주식회사 헬릭스미스 네이키드 dna 유전자 요법을 위한 동결 건조된 약제학적 조성물
CA3130213A1 (en) 2019-02-15 2020-08-20 Children's Medical Center Corporation Treating heart failure

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ232813A (en) * 1989-03-10 1992-08-26 Snow Brand Milk Products Co Ltd Human fibroblast glycoprotein, cell differentiation, blood vessel endothelial cell growth factor, cellular immunology inforcing factor of 78 or 74 thousand daltons plus or minus two thousand daltons
US6673776B1 (en) * 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
US5693622A (en) * 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
CA2022752C (en) * 1989-08-11 1998-07-07 Naomi Kitamura Hepatic parenchymal cell growth factor, gene encoding the same, process for producing the factor, and transformants producing the factor
US6706694B1 (en) * 1990-03-21 2004-03-16 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate
DE69131069T2 (de) * 1990-07-13 1999-07-15 Snow Brand Milk Products Co., Ltd., Sapporo, Hokkaido Plasmid das für die aminosäuresequenz von tcf-ii kodierende dns enthalt, transformierte zelle und produktion einer physiologisch aktiven substanz mit ihrer verwendung
US5661133B1 (en) * 1991-11-12 1999-06-01 Univ Michigan Collateral blood vessel formation in cardiac muscle by injecting a dna sequence encoding an angiogenic protein
US6498144B1 (en) * 1993-10-18 2002-12-24 North Shore - Long Island Jewish Research Institute Use of scatter factor to enhance angiogenesis
US5837676A (en) * 1993-10-18 1998-11-17 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
US5652225A (en) * 1994-10-04 1997-07-29 St. Elizabeth's Medical Center Of Boston, Inc. Methods and products for nucleic acid delivery
US20030148968A1 (en) * 1995-02-28 2003-08-07 Hammond H. Kirk Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
CA2230819C (en) * 1995-08-29 2009-04-14 Sumitomo Pharmaceuticals Co., Ltd. Medicament comprising hgf gene
US5830879A (en) * 1995-10-02 1998-11-03 St. Elizabeth's Medical Center Of Boston, Inc. Treatment of vascular injury using vascular endothelial growth factor
US6121246A (en) * 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
JPH11246433A (ja) * 1998-03-03 1999-09-14 Sumitomo Pharmaceut Co Ltd 心筋梗塞治療剤
US20040228834A1 (en) * 1998-03-09 2004-11-18 Jeffrey Isner Compositions and methods for modulating vascularization
CN1222310C (zh) * 1998-08-05 2005-10-12 住友制药株式会社 肝实质细胞增殖因子药用制剂
KR20000046969A (ko) 1998-12-31 2000-07-25 이선경 이종 유전자 유래의 유전자 발현 조절요소를 포함하는 강력한전사 활성을 가진 진핵세포 발현벡더
CN1182874C (zh) * 1999-10-29 2005-01-05 安增子摩祺株式会社 糖尿病性局部缺血疾病的基因治疗制剂
WO2002000258A1 (en) * 2000-06-27 2002-01-03 Anges Mg, Inc. Medicinal compositions for angiogenic therapy
EP1361896A2 (en) * 2001-01-23 2003-11-19 Boston Scientific Corporation Localized myocardial injection method for treating ischemic myocardium
EP1234583A1 (en) * 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag PEG-conjugates of HGF-NK4
KR100562824B1 (ko) * 2002-03-20 2006-03-23 주식회사 바이로메드 유전자 발현효율이 높으며 간세포 성장인자의 두 가지이형체를 동시에 발현하는 하이브리드 간세포 성장인자유전자
JP2008537942A (ja) * 2005-03-31 2008-10-02 マイトジェン， インコーポレイテッド 心疾患のための処置
US20070212390A1 (en) * 2005-09-22 2007-09-13 Ludwig Institute For Cancer Research Protease-resistant forms of VEGF-D, method of making and method of use
CN101356189A (zh) * 2005-11-10 2009-01-28 受体生物公司 肝细胞生长因子内含子融合蛋白
JP5579164B2 (ja) * 2008-04-09 2014-08-27 ビロメッド カンパニー， リミテッド 凍結乾燥ｄｎａ製剤、組成物、及び凍結乾燥ｄｎａ製剤を製造する方法

Also Published As

Publication number Publication date
KR20100126316A (ko) 2010-12-01
EP2252321A4 (en) 2012-09-05
EP2252321B1 (en) 2015-04-29
WO2009093880A2 (en) 2009-07-30
DK2252321T3 (en) 2015-05-26
EP2252321A2 (en) 2010-11-24
PT2252321E (pt) 2015-07-07
ES2537971T3 (es) 2015-06-16
AU2009206869A1 (en) 2009-07-30
CA2712078C (en) 2015-02-24
CN101925362A (zh) 2010-12-22
CA2712078A1 (en) 2009-07-30
MX2010007887A (es) 2010-08-10
JP5563991B2 (ja) 2014-07-30
RU2448159C1 (ru) 2012-04-20
RU2010135532A (ru) 2012-02-27
AU2009206869B2 (en) 2012-04-19
JP2011510069A (ja) 2011-03-31
WO2009093880A3 (en) 2009-10-29
KR101325674B1 (ko) 2013-11-06
US20090202606A1 (en) 2009-08-13

Similar Documents

Publication Publication Date Title
BRPI0907624A2 (pt) tratamento e prevenção de doenças cardíacas usando duas ou mais isoformas do fator de crescimento de hepatócito
FIC20240036I1 (fi) Geeniterapia, joka ilmentää ihmisen hyytymistekijä IX:n muunnosta R338L
PL2442814T3 (pl) Bifidobacteria do leczenia cukrzycy i pokrewnych chorób
FR2921499B1 (fr) Structure orientable de type catheter ou endoscope
IL241985A0 (en) Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents
HUS1600048I1 (hu) Készítmény Fabry-kór kezelésére
IT1391555B1 (it) Apparato trattamento extracorporeo sangue
EP2278999C0 (en) EAR PREPARATIONS FOR THE TREATMENT OF EAR DISEASES AND CONDITIONS
IL209336B (en) Compositions for treating hyperproliferative diseases and uses thereof
HUE039731T2 (hu) l,3-difenilprop-2-én-l-on-származékok alkalmazása májbetegségek kezelésére
HUE061548T2 (hu) Komplementtel összefüggõ rendellenességek kezelésére szolgáló eljárások és készítmények
HRP20190031T1 (hr) Sintetski triterpenoidi i postupci njihove upotrebe u liječenju bolesti
BRPI1012116A2 (pt) composição farmacêutica para o tratamento de doenças cardíacas
IL217540A (en) Oral composition for use in oral disinfection or in treating an oral disease
BR112012002124A2 (pt) tratamento da doença de crohn com laquinimode.
BRPI0810270A2 (pt) "implante de válvula cardíaca e método de implante"
PL2037902T3 (pl) Zastosowanie kanabidiolu w użyciu w leczeniu bólu neuropatycznego
DK2245199T3 (da) Anvendelse af mikrovesikler i diagnosticering, prognosticering og behandling af medicinske sygdomme og tilstande
BRPI0911004A2 (pt) Artigo antimicrobiano, líquido de tratamento e métodos de preparação dos mesmos
DK2222272T3 (da) Behandling af luftvejssygdom
BRPI0815551A2 (pt) Tratamento através de hucbc de doença beta-amiloide
BRPI1008517A2 (pt) direcionamento duplo de mir-208 e mir-499 no tratamento de doenças cardíacas.
EP2091480A4 (en) SYSTEM FOR THE TREATMENT OF HEART TISSUE
PL2234631T3 (pl) Związki i metody stosowane w terapii choroby naczyniowej
FR2934052B1 (fr) Dosage de l'activite du facteur tissulaire circulant

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B25D Requested change of name of applicant approved

Owner name: HELIXMITH CO., LTD (KR)

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25G Requested change of headquarter approved

Owner name: HELIXMITH CO., LTD (KR)

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]